Kevin Kalinsky, MD, MS, FASCO, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-04
ASCO 2026
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer (Abstract LBA1000).
The ASCO Post Staff
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included in the Plenary Session.
The ASCO Post Staff
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
The ASCO Post Staff
Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab in patients with anti–PD-(L)1–refractory Merkel cell carcinoma (Abstract LBA9514).
Hannah L. Kenny, MD, and Joseph M. Curry, MD, both of Thomas Jefferson University Hospital, discuss results of a phase II trial of neoadjuvant cemiplimab-rwlc in patients with hedgehog inhibitor–naive basal cell carcinoma (BCC) of the head and neck (Abstract 9515).
The ASCO Post Staff
Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).